Related Experiment Video

Updated: May 20, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET

Paul Slobbe1, Alex J Poot, Albert D Windhorst

  • 1Department of Nuclear Medicine and PET Research, VU University Medical Center, Amsterdam, The Netherlands. p.slobbe@vumc.nl

Drug Discovery Today
|July 7, 2012
PubMed

Insights

Positron emission tomography (PET) with radiolabeled tyrosine kinase inhibitors (TKIs) enables precise tracking and quantification of drug behavior. This TKI-PET imaging approach shows promise for enhancing personalized cancer therapy efficacy.

Area of Science:

  • Oncology
  • Radiochemistry
  • Pharmacology

Background:

  • Small molecule tyrosine kinase inhibitors (TKIs) are crucial cancer therapeutics, but their efficacy is limited.
  • Personalized medicine approaches are needed to improve treatment outcomes for TKIs.

Purpose of the Study:

  • To provide an overview of tracer synthesis and development for TKI-PET.
  • To describe preclinical and early clinical applications of TKI-PET for cancer treatment.

Main Methods:

  • Overview of tailor-made tracer synthesis strategies for individual TKIs.
  • Review of preclinical studies involving TKI-PET.
  • Analysis of initial proof-of-principle clinical TKI-PET studies.

Main Results:

  • Each TKI necessitates a unique, customized approach for radiolabeling and tracer development.
  • Preclinical data demonstrate the feasibility of TKI-PET for in vivo drug tracking.
  • Early clinical studies indicate TKI-PET's potential for understanding drug-target interactions.

Conclusions:

  • TKI-PET offers a powerful method for in vivo drug tracking and quantification.
  • This imaging technique has the potential to significantly improve personalized cancer treatment strategies.
  • Further development and application of TKI-PET can enhance therapeutic efficacy.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET